EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comorbidities in Mild WAS / XLT Require Lifelong Follow‐Up and Consideration of Definitive Treatment

Coralie Mallebranche iD, Charline Miot, Mickael Alligon, Despina Moshous, Benedicte Neven, Vincent Barlogis, Virginie Courteille, Bénédicte Bruno, Marie Ouachée-Chardin, Dalila Adjaoud, Yves Delneste, Olivier Bouaziz und 5 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.70061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Coralie Mallebranche und 16 weiteren Autor:innen. Beteiligte Einrichtung: Université D'angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT, Angers, France. Hauptthemen laut MEDLINE: Wiskott-Aldrich Syndrome, Thrombocytopenia, Genetic Diseases, X-Linked. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loss of function mutations in the gene encoding WASP (Wiskott‐Aldrich syndrome protein) result in Wiskott‐Aldrich syndrome (WAS) and X‐linked thrombocytopenia‐XLT (WAS/XLT). The clinical severity of the disease can be assessed using the WAS clinical severity score. Typically, patients with a score of 3 or less at 2 years of age are considered to have mild WAS/XLT disease. However, patients with a low score in the first 2 years of life can still experience life‐threatening complications, and there are no agreed guidelines for the management of these patients with mild WAS/XLT. We analyzed data on WAS/XLT patients from the French National Reference Centre for Primary Immunodeficiencies registry. At 10 December 2021, data were available for 261 patients, 170 of whom had mild WAS/XLT. The median age of these patients at last follow‐up was 15.8 years (range 2.0–60.4). Overall survival at 40 years was 73% in mild WAS patients versus 65% in severe WAS patients ( p = 0.43). In the mild WAS population, prior to Hematopoietic Stem Cell Transplantation or gene therapy, 38.2% of patients progressed to a WAS severity score of 4–5 after the age of 2. Remarkably, no deaths were reported in 45 HSCTs performed since 2010, regardless of initial severity, type and HLA compatibility of the transplant, and age at diagnosis, with a median follow‐up of 3.2 years (0–11.5) after transplant. As complications can occur throughout life, our study supports definitive treatment for all patients when available, including those with mild forms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wiskott-Aldrich SyndromeThrombocytopeniaGenetic Diseases, X-LinkedHumansMaleChild, PreschoolFemaleChildAdultAdolescentFollow-Up StudiesMiddle AgedInfantHematopoietic Stem Cell TransplantationComorbidityYoung AdultRegistriesSeverity of Illness IndexWiskott-Aldrich Syndrome ProteinFrance

Stichwörter der Autor:innen

Wiskott‐Aldrich syndrome (WAS)X‐linked thrombocytopeniahematopoietic stem cell transplantationprimary immunodeficiency

Substanzen

Wiskott-Aldrich Syndrome Protein

Autor:innen und Institutionen

  • Université D'angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT, Angers, France.
  • CHU Angers, Pediatric Immuno-Hemato-Oncology Unit, Angers, France.
  • CHU Angers, Laboratory of Immunology and Allergology, Angers, France.
  • French National Reference Centre for Primary Immunodeficiencies (CEREDIH), Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • Imagine Institute, Université de Paris Cité, Paris, France.
  • Pediatric Immunology, Hematology and Rheumatology Unit, Necker Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

ORCID-Profile: Coralie Mallebranche

Zitieren

APA

Mallebranche, C., Miot, C., Alligon, M., Moshous, D., Neven, B., Barlogis, V., Courteille, V., Bruno, B., Ouachée-Chardin, M., Adjaoud, D., Delneste, Y., Bouaziz, O., Picard, C., Fischer, A., Mahlaoui, N., Pellier, I., & Members of the CEREDIH French PID Study Group (2025). Comorbidities in Mild WAS / XLT Require Lifelong Follow‐Up and Consideration of Definitive Treatment. American Journal of Hematology. https://doi.org/10.1002/ajh.70061

Vancouver

Mallebranche C, Miot C, Alligon M, Moshous D, Neven B, Barlogis V, et al. Comorbidities in Mild WAS / XLT Require Lifelong Follow‐Up and Consideration of Definitive Treatment. American Journal of Hematology. 2025. doi:10.1002/ajh.70061

BibTeX
@article{Mallebranche2025,
  author = {Mallebranche, Coralie and Miot, Charline and Alligon, Mickael and Moshous, Despina and Neven, Benedicte and Barlogis, Vincent and Courteille, Virginie and Bruno, Bénédicte and Ouachée-Chardin, Marie and Adjaoud, Dalila and Delneste, Yves and Bouaziz, Olivier and Picard, Capucine and Fischer, Alain and Mahlaoui, Nizar and Pellier, Isabelle and Members of the CEREDIH French PID Study Group, Members of the CEREDIH French PID Study Group},
  title = {Comorbidities in Mild WAS / XLT Require Lifelong Follow‐Up and Consideration of Definitive Treatment},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.70061}
}
Kostenlos starten →